Bad Pharma And The Statin Wars 4

It’s been amusing to watch former Pfizer executive John LaMattina try to pick apart Ben Goldacre’s new book, Bad Pharma,  a powerful indictment of the industry in which LaMattina used to work. This is not the occasion to get into the details of this battle, but as an aside let me just say that I would advise any representatives of the pharmaceutical industry to think very carefully before choosing to take on Goldacre.

What I want to focus on here is an assertion, accepted by both Goldacre and LaMattina, that is simply mistaken. LaMattina’s latest post is a response to a brief statement by Goldacre in his book that there has never been a head-to-head clinical trial comparing statins. Both writers accept this statement as a fact.

I think it is very curious that neither Goldacre not LaMattina remember the PROVE-IT TIMI 22 trial published in NEJM in 2004.

Click here to read the full post on Forbes.

John LaMattina

John LaMattina

Dr Ben Goldacre, author of the Bad Science col...

Ben Goldacre



  1. Really, the point should be that we have good evidence statins work in secondary prevention and less evidence they work in primary prevention. Also, the whole titrating statins to target LDL goals is garbage and is a waste of time. We also should include that fibrates, niacin, and zetia are not helpful.

    Regarding head to head statin trials, Crestor and Lipitor were just compared in last few years with regards to plaque regression or Carotid intimal thickness I believe.

What do you think?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s